Molecular and Cellular Biochemistry

, Volume 266, Issue 1–2, pp 151–159

Trigonella foenum graecum seed powder protects against histopathological abnormalities in tissues of diabetic rats

  • Shalini Thakran
  • M.R. Siddiqui
  • Najma Z. Baquer

Abstract

Trigonella foenum graecum is a well-known hypoglycemic agent used in traditional Indian medicines. It was previously reported that oral administration of its seed powder for 3 weeks to alloxan diabetic rats stabilized glucose homeostasis and free radical metabolism in liver and kidney. In the present study, we further investigated the effects of 3 weeks alloxan induced diabetes on the histological structure and function of liver and kidney and the protective effect of T. foenum graecumseed powder (TSP) oral administration to the diabetic rats utilizing enzyme analysis and light and transmission electron microscopy. The activity of the enzyme, glutamate dehydrogenase was significantly higher whereas the activity of d-β-hydroxybutyrate dehydrogenase enzyme was significantly lower in liver and kidney of alloxan-induced diabetic rats. Histopathological studies showed liver degenerative and early nephropathic changes in diabetic rats. Ultrastructure of the diabetic liver revealed a reduction in the rough endoplasmic reticulum and swelling of mitochondria in the hepatocytes. TSP treatment to the diabetic rats effectively prevented the alteration in the activities of the two enzymes and partially prevented the structural abnormalities thus suggesting a protective effect of TSP on the liver and kidney of the diabetic rats. The role of TSP in reversing the diabetic state at the cellular level besides the metabolic normalization further proves its potential as an antidiabetic agent (Mol Cell Biochem 266: 151–159, 2004)

diabetes Trigonella foenum graecum histopathology enzyme changes 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Saltiel AR, Kahn CR: Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414(6865): 799–806, 2001Google Scholar
  2. 2.
    Sochor M, Baquer NZ, McLean P: Glucose over-and underutilization in diabetes: Comparative studies on the change in activities of enzymes of glucose metabolism in rat kidney and liver. Mol Physiol 7: 51–68, 1985Google Scholar
  3. 3.
    Baquer NZ, Gupta D, Raju J: Regulation of metabolic pathways in liver and kidney during experimental diabetes: Effects of antidiabetic compounds. Indian J. Clin Biochem 13(2): 63–80, 1998Google Scholar
  4. 4.
    Brownlee M: The pathological implications of protein glycation. Clin Invest Med 18(4): 275–281, 1995Google Scholar
  5. 5.
    King GL, Brownlee M: The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin North Am 25(2): 255–270, 1996Google Scholar
  6. 6.
    Kume E, Ohmachi Y, Itagaki S, Tamura K, Doi K: Hepatic changes of mice in the subacute phase of streptozotocin (SZ)-induced diabetes. Exp Toxicol Pathol 46(4–5): 368–374, 1994Google Scholar
  7. 7.
    Kordowiak AM, Nikiforuk A, Dabros W:Biochemical and morphological study on liver Golgi complex in streptozotocin-diabetic and control rats treated with bis(kojato)oxovanadium(IV)[VO(ka)2]⨰ 2H2O. Part I. One week treatment with vanadium compound. Pol J Pathol 51(1):9–16,2000Google Scholar
  8. 8.
    Mifsud SA, Allen TJ, Bertram JF, Hulthen UL, Kelly DJ, Cooper ME, Wilkinson-Berka JL, Gilbert RE: Podocyte foot process broadening in experimental diabetic nephropathy: Amelioration with reninangiotensin blockade. Diabetologia 44(7): 878–882, 2001Google Scholar
  9. 9.
    Dabros W, Dziga D, Grybos R, Kordowiak AM: Biochemical and morphological alterations in rat liver Golgi complexes after treatment with bis(maltolato)oxovanadium(IV) [BMOV] or maltol alone. Pathol Res Pract 196(8): 561–568, 2000.Google Scholar
  10. 10.
    Dabros W, Kajda B, Kordowiak AM: Control and STZ-diabetic rat liver Golgi complexes under the influence of bis(2, 2'-bipyridine) oxovanadium( IV) sulphate. The morphological investigation. Pol J Pathol 53(3): 123–128, 2002Google Scholar
  11. 11.
    Obineche EN, Mensah-Brown E, Chandranath SI, Ahmed I, Naseer O, Adem A: Morphological changes in the rat kidney following long-term diabetes. Arch Physiol Biochem 109(3): 241–245, 2001Google Scholar
  12. 12.
    Garfield SA, Cardell Jr RR: Hepatic glucose-6-phosphatase activities and correlated ultrastructural alterations in hepatocytes of diabetic rats. Diabetes 28(7): 664–679, 1979Google Scholar
  13. 13.
    Grover JK, Yadav S, Vats V: Medicinal plants of India with anti-diabetic potential. J Ethnopharmacol 81(1): 81–100, 2002Google Scholar
  14. 14.
    Oubre AY, Carlson TJ, King SR, Reaven GM: From plant to patient: An ethnomedical approach to the identification of new drugs for the treatment of NIDDM. Diabetologia 40: 614–617, 1997Google Scholar
  15. 15.
    Khosla P, Gupta DD, Nagpal RK: Effect of Trigonella foenum graecum (Fenugreek) on blood glucose in normal and diabetic rats. Indian J Physiol Pharmacol 39(2): 173–174, 1995Google Scholar
  16. 16.
    Puri D, Prabhu KM, Murthy PS: Hypocholesterolemic effect of the hypoglycemic principle of fenugreek (Trigonella foenum graecum) seeds. Indian J Clin Biochem 9: 13–16, 1995Google Scholar
  17. 17.
    Stark A, Madar Z: The effect of an ethanol extract derived from fenugreek (Trigonella foenum graecum) on bile acid absorption and cholesterol levels in rats. Br J Nutr 69(1): 277–287, 1993Google Scholar
  18. 18.
    Puri D, Prabhu KM, Murthy PS: Mechanism of action of a hypoglycemic principle isolated from fenugreek seeds. Indian J Physiol Pharmacol 46(4): 457–462, 2002Google Scholar
  19. 19.
    Duke JA: Handbook of Phytochemical Constituents of GRAS Herbs and Other Economic Plants. CRC Press, Boca Raton, Fl, 1992Google Scholar
  20. 20.
    Petit PR, Sauvaire YD, Hillaire-Buys DM, Leconte OM, Baissac YG, Ponsin GR, Ribes GR: Steroid saponins from fenugreek seeds: Extraction, purification, and pharmacological investigation on feed-ing behavior and plasma cholesterol. Steroids 60(10): 674–680, 1995Google Scholar
  21. 21.
    Al-Habori M, Raman A, Lawrence MJ, Skett P: in vitro effect of fenugreek extracts on intestinal sodium-dependent glucose uptake and hepatic glycogen phosphorylase A. Int J Exp Diabetes Res 2(2): 91–99, 2001Google Scholar
  22. 22.
    Sauvaire Y, Petit P, Broca C, Manteghetti M, Baissac Y, Fernandez-Alvarez J, Gross R, Roye M, Leconte A, Gomis R, Ribes G: 4-Hydroxyisoleucine: A novel amino acid potentiator of insulin secretion. Diabetes 47(2): 206–210, 1998Google Scholar
  23. 23.
    Broca C, Gross R, Petit P, Sauvaire Y, Manteghetti M, Tournier M, Masiello P, Gomis R, Ribes G: 4-Hydroxyisoleucine: Experimental evidence of its insulinotropic and antidiabetic properties. Am J Physiol 77(4): E617–E623, 1999Google Scholar
  24. 24.
    Phytochemical Database, USDA-ARS-NGRL, Beltsville Agricultural Research Center, Beltsville, MDGoogle Scholar
  25. 25.
    Raju J, Gupta D, Rao AR, Yadava PK, Baquer NZ: Trigonella foenum graecum (fenugreek) seed powder improves glucose homeostasis in alloxan diabetic rat tissues by reversing the altered glycolytic, gluconeogenic and lipogenic enzymes. Mol Cell Biochem 224(1–2): 45–51, 2001Google Scholar
  26. 26.
    Genet S, Kale RK, Baquer NZ: Alterations in antioxidant enzymes and oxidative damage in experimental diabetic rat tissues: Effect of vanadate and fenugreek (Trigonellafoenum graecum). Mol Cell Biochem 236 (1–2): 7–12, 2002Google Scholar
  27. 27.
    Thakran S, Salimuddin, Baquer NZ: Oral administration of orthovana-date and Trigonella foenum graecum seed powder restore the activities of mitochondrial enzymes in tissues of alloxan-induced diabetes. Mol Cell Biochem 247: 45–53, 2003Google Scholar
  28. 28.
    Anuradha CV, Ravikumar P: Restoration on tissue antioxidants by fenugreek seeds (Trigonella foenum graecum)inalloxan-diabetic rats. Indian J Physiol Pharmacol 45(4): 408–420, 2001Google Scholar
  29. 29.
    Vats V, Yadav SP, Grover JK: Effect of T. foenum graecum on glycogen content of tissues and the key enzymes of carbohydrate metabolism. J Ethnopharmocol 85(2–3): 237–242, 2003Google Scholar
  30. 30.
    Sochor M, Baquer NZ, McLean P: Glucose overutilization in diabetes: Evidence from studies on the changes in hexokinase, the pentose phosphate pathway and glucuronate-xylulose pathway in rat kidney cortex in diabetes. Biochem Biophys Res Commun 86(1): 32–39,1979Google Scholar
  31. 31.
    Salimuddin, Upadhyaya KC, Baquer NZ: Effects of vanadate and insulin on the activities of selected enzymes of amino acid metabolism in alloxan diabetic rat kidney. Biochem Mol Biol Int 40(4): 853–860, 1996Google Scholar
  32. 32.
    Brignone JA, de Brignone CM, de Mignone IR, Ricci CR, Susemihl MC, Rodriguez RR: Improving effects obtained by the ovariectomy or treatment with tamoxifen of female diabetic rats over the function and enzyme activities of liver mitochondria. Horm Metab Res 23(2): 56–61, 1991Google Scholar
  33. 33.
    Pearse AGE: Histochemistry: Theoretical and Applied (1) J&A Churchill Ltd., pp. 576 1968Google Scholar
  34. 34.
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the folin phenol reagent. J Biol Chem 193: 265–275, 1951Google Scholar
  35. 35.
    Steer KA, Sochor M, Gonzalez AM, McLean P: Regulation of pathways of glucose metabolism in kidney. Specific linking of pentose phosphate pathway activity with kidney growth in experimental diabetes and unilateral nephrectomy. FEBS Lett 50(2): 494–498, 1982Google Scholar
  36. 36.
    Cortes P, Dumler F, Venkatachalam KK, Goldman J, Sastry KS, Venkatachalam H, Bernstein J, Levin NW: Alterations in glomerular RNA in diabetic rats: Roles of glucagon and insulin. Kidney Int 20(4): 491–499, 1981Google Scholar
  37. 37.
    Jefferson LS: Lilly lecture 1979: Role of insulin in the regulation of protein synthesis. Diabetes 29(6): 487–496, 1980Google Scholar
  38. 38.
    Khandelwal RL, Zinman SM, Knull HR: The effect of streptozotocin-induced diabetes on glycogen metabolism in rat kidney and its relationship to the liver system. Arch Biochem Biophys 97(1): 310–316, 1979Google Scholar
  39. 39.
    Salimuddin, Upadhyaya KC, Baquer NZ: Effects of vanadate on expression of liver arginase in experimental diabetic rats. IUBMB Life 48(2): 237–240, 1999Google Scholar
  40. 40.
    Salimuddin, Upadhyaya KC, Baquer NZ: Effects of vanadate and insulin on the activities of selected enzymes of amino acid metabolism in alloxan diabetic rat kidney. Biochem Mol Biol Int 40(4): 853–860, 1996Google Scholar
  41. 41.
    Churchill P, McIntyre JO, Vidal JC, Fleischer S: Basis for decreased D-beta-hydroxybutyrate dehydrogenase activity in liver mitochondria from diabetic rats. Arch Biochem Biophys 224(2): 659–670, 1983Google Scholar
  42. 42.
    Vidal JC, McIntyre JO, Churchill P, Andrew JA, Pehuet M, Fleischer S: Influence of diabetes on rat liver mitochondria: Decreased unsaturation of phospholipid and D-beta-hydroxybutyrate dehydrogenase activity. Arch Biochem Biophys 224(2): 643–658, 1983Google Scholar
  43. 43.
    Harano Y, DePalma RG, Lavine L, Miller M: Fatty acid oxidation, oxidative phosphorylation and ultrastructure of mitochondria in the diabetic rat liver. Hepatic factors in diabetic ketosis. Diabetes 21(5): 257–270, 1972Google Scholar
  44. 44.
    Laguens RP, Candela S, Hernandez RE, Gagliardino JJ: Streptozotocin-induced liver damage in mice. Horm Metab Res 12(5): 197–201, 1980Google Scholar
  45. 45.
    McCall AL: The impact of diabetes on the CNS. Diabetes 41(5): 557–570, 1992Google Scholar
  46. 46.
    Ahmed I, Adeghate E, Sharma AK, Pallot DJ, Singh J: Effects of Momordica charantia fruit juice on islet morphology in the pancreas of the streptozotocin-diabetic rat. Diabetes Res Clin Pract 40(3): 145–151, 1998Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Shalini Thakran
    • 1
  • M.R. Siddiqui
    • 1
  • Najma Z. Baquer
    • 1
  1. 1.Hormone and Drug Research Laboratory, School of Life SciencesJawaharlal Nehru UniversityNew delhiIndia

Personalised recommendations